Healthcare / Medical DevicesHKSE
$1.68
-0.01 (-0.59%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-37.4M · quality 74.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-7.3%
↓Gross Margin
65.0%
↑Debt/Equity
0.91
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.2%
FCF CAGR
—
FCF margin
-67.1%
FCF / Net income
2.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $57.0M · net income $-18.8M · FCF $-38.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $57.0M | $57.0M | $50.8M | $47.4M | $36.4M |
| Net Income | $-18.8M | $-18.8M | $-6.9M | $-66.5M | $-65.9M |
| EBITDA | $-2.2M | $-2.2M | $6.3M | $-54.5M | $-53.3M |
| EPS | -0.20 | -0.20 | -0.01 | -0.14 | -0.14 |
| Gross Margin | 65.0% | 65.0% | 69.5% | 68.4% | 64.6% |
| Operating Margin | -35.9% | -35.9% | -44.2% | -104.6% | -132.2% |
| Net Margin | -33.0% | -33.0% | -13.7% | -140.2% | -181.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.91 | 0.91 | 0.04 | 0.03 | 0.03 |
| Current Ratio | 2.52 | 2.52 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-38.3M | $-38.3M | $-37.4M | $-33.5M | $-33.6M |
| Returns | |||||
| ROE | -7.3% | -7.3% | -2.3% | -20.2% | -16.5% |
| Valuation | |||||
| EV/EBITDA | — | — | 251.69 | — | — |
| P/B | 0.65 | 0.65 | 5.23 | 11.47 | 16.77 |
| Growth & Yield | |||||
| Revenue Growth | 12.3% | 12.3% | 7.1% | 30.4% | — |
| EPS Growth | -1360.1% | -1360.1% | 90.3% | -2.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-56.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.20
Residual
-56.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.